CASP3 and Parkinson disease: As seen in Figure 6C, co-treatment with azilsartan (5 mg/kg/d) also attenuated the activation of caspase-3 in the SN of PD rats, since its activity was reduced by 1.6-fold (P < 0.05) after azilsartan treatment.